{"id":72128,"date":"2026-08-10T12:23:03","date_gmt":"2026-08-10T04:23:03","guid":{"rendered":"https:\/\/flcube.com\/?p=72128"},"modified":"2026-08-10T12:23:04","modified_gmt":"2026-08-10T04:23:04","slug":"daiichi-sankyo-enlists-innovent-biologics-as-exclusive-china-partner-for-vanflyta-flt3-inhibitor-in-aml","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72128","title":{"rendered":"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Daiichi Sankyo Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4568:TYO\">TYO:\u202f4568<\/a>) and <strong>Innovent Biologics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1801:HKG\">HKG:\u202f1801<\/a>) announced an <strong>exclusive entrusted promotion agreement<\/strong> for the commercialization of <strong>Vanflyta (Quizartinib Hydrochloride Tablets)<\/strong> in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.<\/p>\n\n\n\n<h2 id=\"h-deal-snapshot\" class=\"wp-block-heading\">Deal Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Daiichi Sankyo (TYO:\u202f4568) &amp; Innovent Biologics (HKG:\u202f1801)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Exclusive entrusted promotion<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Vanflyta (Quizartinib Hydrochloride Tablets)<\/td><\/tr><tr><td><strong>Market<\/strong><\/td><td>Mainland China<\/td><\/tr><tr><td><strong>Daiichi Sankyo Role<\/strong><\/td><td>Clinical development, manufacturing, supply<\/td><\/tr><tr><td><strong>Innovent Role<\/strong><\/td><td>Exclusive promotion rights; leads commercial efforts<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>10\u202fAug\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Oral, potent <strong>type\u202fII FLT3 inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>FLT3\u2011ITD<\/strong> (FMS\u2011like tyrosine kinase\u202f3 internal tandem duplication) mutation<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Selective inhibition of the FLT3\u2011ITD mutation, which is present in roughly <strong>25\u202f% of adult AML cases<\/strong>; the type\u202fII binding mode distinguishes it from earlier FLT3 agents by stabilizing the inactive kinase conformation.<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Developed and supplied by <strong>Daiichi Sankyo<\/strong>; promotion rights licensed to Innovent in China.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-amp-clinical-backdrop\" class=\"wp-block-heading\">Regulatory &amp; Clinical Backdrop<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Approval Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>June\u202f2026<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult patients with newly diagnosed AML who are <strong>FLT3\u2011ITD positive<\/strong> (confirmed by fully validated test)<\/td><\/tr><tr><td><strong>Induction Phase<\/strong><\/td><td>In combination with standard\u2011dose cytarabine + anthracyclines<\/td><\/tr><tr><td><strong>Consolidation Phase<\/strong><\/td><td>In combination with cytarabine<\/td><\/tr><tr><td><strong>Maintenance Phase<\/strong><\/td><td>Single\u2011agent therapy following consolidation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The three\u2011phase positioning \u2014 spanning induction, consolidation, and maintenance \u2014 gives Vanflyta a broader treatment arc than many competitors limited to later\u2011line or maintenance\u2011only settings.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China AML Landscape:<\/strong> AML remains one of the most aggressive hematologic malignancies in China, with FLT3\u2011ITD mutations conferring poor prognosis. An oral targeted therapy integrated across all treatment phases addresses a significant unmet need.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts estimate the China FLT3\u2011targeted therapy market could reach <strong>\u00a53\u20134\u202fbillion<\/strong> (\u2248\u202fUS$420\u2013560\u202fmillion) annually by 2028, with Vanflyta positioned to capture a meaningful share given its full\u2011arc indication.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Vanflyta\u2019s approval across induction, consolidation, and maintenance phases differentiates it from agents restricted to relapse\/refractory or post\u2011consolidation settings.<\/li>\n\n\n\n<li><strong>Strategic Rationale:<\/strong> For Daiichi Sankyo, the partnership leverages Innovent\u2019s established hematology commercial infrastructure and hospital relationships without the capital outlay of building a dedicated China sales force. For Innovent, the deal adds a revenue\u2011generating promoted asset amid a challenging funding environment for Chinese biotechs.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the commercial potential of Vanflyta in China and the anticipated benefits of the Daiichi Sankyo\u2013Innovent partnership. Actual results may differ materially due to regulatory developments, competitive dynamics, reimbursement negotiations, and market acceptance. The companies have not disclosed revenue forecasts or deal economics. Investors should consult official filings for updated risk factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo Co., Ltd. (TYO:\u202f4568) and Innovent Biologics, Inc. (HKG:\u202f1801) announced an exclusive entrusted promotion&#8230;<\/p>\n","protected":false},"author":1,"featured_media":72136,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,11],"tags":[194,910,198,978],"class_list":["post-72128","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-daiichi-sankyo","tag-hkg-1801","tag-innovent-biologics","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo Co., Ltd. (TYO:\u202f4568) and Innovent Biologics, Inc. (HKG:\u202f1801) announced an exclusive entrusted promotion agreement for the commercialization of Vanflyta (Quizartinib Hydrochloride Tablets) in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72128\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo Co., Ltd. (TYO:\u202f4568) and Innovent Biologics, Inc. (HKG:\u202f1801) announced an exclusive entrusted promotion agreement for the commercialization of Vanflyta (Quizartinib Hydrochloride Tablets) in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72128\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T04:23:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T04:23:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML\",\"datePublished\":\"2026-08-10T04:23:03+00:00\",\"dateModified\":\"2026-08-10T04:23:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128\"},\"wordCount\":474,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1001.webp\",\"keywords\":[\"Daiichi Sankyo\",\"HKG: 1801\",\"Innovent Biologics\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72128#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72128\",\"name\":\"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1001.webp\",\"datePublished\":\"2026-08-10T04:23:03+00:00\",\"dateModified\":\"2026-08-10T04:23:04+00:00\",\"description\":\"Daiichi Sankyo Co., Ltd. (TYO:\u202f4568) and Innovent Biologics, Inc. (HKG:\u202f1801) announced an exclusive entrusted promotion agreement for the commercialization of Vanflyta (Quizartinib Hydrochloride Tablets) in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72128\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72128#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML - Insight, China&#039;s Pharmaceutical Industry","description":"Daiichi Sankyo Co., Ltd. (TYO:\u202f4568) and Innovent Biologics, Inc. (HKG:\u202f1801) announced an exclusive entrusted promotion agreement for the commercialization of Vanflyta (Quizartinib Hydrochloride Tablets) in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72128","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML","og_description":"Daiichi Sankyo Co., Ltd. (TYO:\u202f4568) and Innovent Biologics, Inc. (HKG:\u202f1801) announced an exclusive entrusted promotion agreement for the commercialization of Vanflyta (Quizartinib Hydrochloride Tablets) in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.","og_url":"https:\/\/flcube.com\/?p=72128","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-10T04:23:03+00:00","article_modified_time":"2026-08-10T04:23:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72128#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72128"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML","datePublished":"2026-08-10T04:23:03+00:00","dateModified":"2026-08-10T04:23:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72128"},"wordCount":474,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=72128#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1001.webp","keywords":["Daiichi Sankyo","HKG: 1801","Innovent Biologics","TYO: 4568"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72128#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72128","url":"https:\/\/flcube.com\/?p=72128","name":"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=72128#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=72128#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1001.webp","datePublished":"2026-08-10T04:23:03+00:00","dateModified":"2026-08-10T04:23:04+00:00","description":"Daiichi Sankyo Co., Ltd. (TYO:\u202f4568) and Innovent Biologics, Inc. (HKG:\u202f1801) announced an exclusive entrusted promotion agreement for the commercialization of Vanflyta (Quizartinib Hydrochloride Tablets) in mainland China. Under the deal, Daiichi Sankyo retains responsibility for clinical development, manufacturing, and supply, while Innovent secures exclusive promotion rights and will lead all commercial efforts in the Chinese market. Financial terms were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72128#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72128"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=72128#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1001.webp","width":1080,"height":608,"caption":"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72128#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo Enlists Innovent Biologics as Exclusive China Partner for Vanflyta FLT3 Inhibitor in AML"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72128"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72128\/revisions"}],"predecessor-version":[{"id":72137,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72128\/revisions\/72137"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/72136"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}